糖尿病预防计划中非传统生物标志物与新发糖尿病:生活方式与二甲双胍干预效果的比较
在糖尿病预防计划(DPP)随机临床试验中,比较安慰剂、生活方式和二甲双胍干预组中炎症、内皮和脂肪细胞功能障碍及凝血相关循环生物标志物与新发糖尿病的关联。结果显示,E-选择素、脂联素和组织型纤溶酶原激活物在安慰剂组与糖尿病发生独立相关,但仅脂联素关联在生活方式和二甲双胍组中维持。
要点
- 脂联素与新发糖尿病关联在生活方式和二甲双胍干预中持续存在。
- E-选择素仅在安慰剂组与糖尿病发生相关,干预后关联消失。
- 二甲双胍组IL-6变化和生活方式组基线瘦素显示新关联。
核心结论
- 脂联素与新发糖尿病关联在三种干预组中均存在,支持其与糖尿病发展的联系。
- 内皮功能障碍标志物E-选择素仅在安慰剂组相关,干预后关联消失,不支持其核心作用。
- 不同干预措施可差异修饰生物标志物与新发糖尿病的关联。
研究设计与样本
- 糖尿病预防计划(DPP)随机对照试验,纳入3234例糖耐量受损个体。
- 随机分为安慰剂、二甲双胍(850 mg每日两次)和强化生活方式组,平均随访3.2年。
- 基线及1年时用特异性免疫分析法测定9种生物标志物,用Cox比例风险模型评估关联。
主要发现
- 安慰剂组中,E-选择素(HR 1.19 [95% CI 1.06, 1.34])、脂联素(0.84 [0.71, 0.99])和组织型纤溶酶原激活物(1.13 [1.03, 1.24])与新发糖尿病独立相关。
- 生活方式组中脂联素关联维持(0.69 [0.52, 0.92]),二甲双胍组中亦维持(0.79 [0.66, 0.94])。
- E-选择素在生活方式和二甲双胍组中均与新发糖尿病无关。
- 二甲双胍组IL-6变化(1.09 [1.021, 1.173])和生活方式组基线瘦素(1.31 [1.06, 1.63])显示新关联。
临床怎么用
- 脂联素可作为预测糖尿病风险的稳定生物标志物,不受生活方式或二甲双胍干预影响。
- 内皮功能障碍标志物在干预后预测价值有限,临床评估应结合干预状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: We compared the associations of circulating biomarkers of inflammation, endothelial and adipocyte dysfunction and coagulation with incident diabetes in the placebo, lifestyle and metformin intervention arms of the Diabetes Prevention Program, a randomised clinical trial, to determine whether reported associations in general populations are reproduced in individuals with impaired glucose tolerance, and whether these associations are independent of traditional diabetes risk factors. We further investigated whether biomarker-incident diabetes associations are influenced by interventions that alter pathophysiology, biomarker concentrations and rates of incident diabetes. METHODS: The Diabetes Prevention Program randomised 3234 individuals with impaired glucose tolerance into placebo, metformin (850 mg twice daily) and intensive lifestyle groups and showed that metformin and lifestyle reduced incident diabetes by 31% and 58%, respectively compared with placebo over an average follow-up period of 3.2 years. For this study, we measured adiponectin, leptin, tissue plasminogen activator (as a surrogate for plasminogen activator inhibitor 1), high-sensitivity C-reactive protein, IL-6, monocyte chemotactic protein 1, fibrinogen, E-selectin and intercellular adhesion molecule 1 at baseline and at 1 year by specific immunoassays. Traditional diabetes risk factors were defined as family history, HDL-cholesterol, triacylglycerol, BMI, fasting and 2 h glucose, HbA1c, systolic blood pressure, inverse of fasting insulin and insulinogenic index. Cox proportional hazard models were used to assess the effects of each biomarker on the development of diabetes assessed semi-annually and the effects of covariates on these. RESULTS: E-selectin, (HR 1.19 [95% CI 1.06, 1.34]), adiponectin (0.84 [0.71, 0.99]) and tissue plasminogen activator (1.13 [1.03, 1.24]) were associated with incident diabetes in the placebo group, independent of diabetes risk factors. Only the association between adiponectin and diabetes was maintained in the lifestyle (0.69 [0.52, 0.92]) and metformin groups (0.79 [0.66, 0.94]). E-selectin was not related to diabetes development in either lifestyle or metformin groups. A novel association appeared for change in IL-6 in the metformin group (1.09 [1.021, 1.173]) and for baseline leptin in the lifestyle groups (1.31 [1.06, 1.63]). CONCLUSIONS/INTERPRETATION: These findings clarify associations between an extensive group of biomarkers and incident diabetes in a multi-ethnic cohort with impaired glucose tolerance, the effects of diabetes risk factors on these, and demonstrate differential modification of associations by interventions. They strengthen evidence linking adiponectin to diabetes development, and argue against a central role for endothelial dysfunction. The findings have implications for the pathophysiology of diabetes development and its prevention.
引用
- Goldberg RB, Bray GA, Marcovina SM, et al. Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions. Diabetologia. 2018. PMID: 30334082. doi:10.1007/s00125-018-4748-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。